

TEGO® Cistus: Daylight defense to protect your DNA

Overexposure to environmental stress like pollution, smoke, harsh weather and sun rays can accelerate skin ageing by triggering oxidative stress in the skin.

To protect your skin against environmental stress Evonik launches TEGO® Cistus which will be presented at the IFSCC Congress 2012. This latest active is a standardized plant extract highly enriched in polyphenols from pink rock rose.

Cistus incanus spp. tauricus grows in Europe and parts of the Middle East and has a historical use in traditional European medicine.

Various *in vitro* studies have shown that TEGO® Cistus delivers strong anti-oxidative and anti-inflammatory effects, reduces reactive oxygen species (ROS) in skin cells and helps to protect the skin against external aggressions, such as UV light and pollution. Extended *in vivo* studies have confirmed that TEGO® Cistus significantly protects the skin from UV induced inflammation and against oxidative stress.

Overall TEGO® Cistus is a natural based active ingredient with proven efficacy with highly scientific claim substantiation for sophisticated anti-ageing products.

Please find appropriate image data and further information on our Personal Care website: www.evonik.com/personal-care

October 26, 2012

Contact persons

Janna Hullmann
Communications Consumer Specialties
Phone +49 201 173-1410
Fax +49 201 173-1838
janna.hullmann@evonik.com

Lisa Dierks
Associate Marketing Manager
Communications/Personal Care
Phone +49 201 173-3170
Fax +49 201 173-713170
lisa.dierks@evonik.com

Evonik Industries AG
Rellinghauser Strasse 1-11
45128 Essen
Germany
www.evonik.com

Chairman of the Supervisory Board
Wilhelm Bonse-Geuking
Executive Board
Dr. Klaus Engel, Chairman
Dr. Wolfgang Colberg,
Dr. Thomas Haeberle, Thomas Wessel,
Patrik Wohlhauser, Dr. Dahai Yu

Registered Office: Essen
Register Court: Essen Local Court
Commercial Registry B 19474
VAT ID no. DE 81 1160003

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (EBITDA) of about €2.8 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.